Loading...
Market
Story
FDA Approves Eli Lilly's Zepbound as First and Only Treatment for Sleep Apnea, Reducing Breathing Interruptions by 25
Dec 20, 2024, 09:55 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval, announced on December 20, 2024, allows Zepbound to be used in conjunction with a reduced-calorie diet and increased physical activity. Clinical data indicates that adults using Zepbound experienced at least 25 fewer breathing interruptions per hour, with up to 50% of patients reporting no symptoms after one year of treatment. The approval may also facilitate broader insurance coverage for the medication, which is primarily recognized for its weight-loss benefits.
View original story
Similar markets
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Moderna • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Approved in US only • 33%
Approved in US and one other major market • 33%
Approved in US and multiple other major markets • 33%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Novo Nordisk • 25%
Sanofi • 25%
Merck • 25%
Other • 25%